Author

A. D. Campbell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:cancer & tumor microenvironment· 7 Organism:mouse· 7 Research Focus:cell type annotation· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:genetic perturbation / CRISPR· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

K. Gilroy· 7 shared O. J. Sansom· 7 shared C. Nixon· 5 shared A. K. Najumudeen· 4 shared C. A. Ford· 4 shared N. Vlahov· 3 shared R. A. Ridgway· 3 shared S. T. Barry· 3 shared

Activity by Year

2020-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersCancer Biology

K. Gilroy

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

C. A. Ford, D. Koludrovic, P. P. Centeno, M. Foth, E. Tsonou, N. Vlahov, N. Sphyris, K. Gilroy, C. Bull, C. Nixon, B. Serrels, A. F. Munro, J. C. Dawson, N. O. Carragher, V. Pavet, , A. D. Campbell

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

bioRxiv · Feb 26, 2024Cancer Biology

eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancers

J. A. Waldron, G. Kanellos, R. C. L. Smith, J. R. P. Knight, J. Munro, C. Alexandrou, N. Vlahov, L. Pardo-Fernandez, M. Moore, S. L. Gillen, D. Strathdee, D. Stevenson, F. C. Warrander, K. Gilroy, C. Nixon, , O. J. Sansom

This study shows eIF4A1 is critical for supporting translational demands in Wnt-driven colorectal cancers, while eIF4A2 loss accelerates tumourigenesis, and eFT226 inhibits eIF4A1 function in these models.

bioRxiv · Nov 10, 2023 · PreprintCancer Biology

Suppression of progesterone by influenza A virus mediates adverse maternal and fetal outcomes in mice

P. S. Creisher, M. A. Parish, J. Lei, J. Liu, J. L. Perry, A. D. Campbell, M. L. Sherer, I. Burd, S. L. Klein

This study shows that influenza A virus suppresses progesterone in pregnant mice, leading to adverse maternal and fetal outcomes, which can be mitigated by progestin treatment.

bioRxiv · Sep 11, 2023Microbiology

KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo

A. K. Najumudeen, S. K. Fey, L. M. Millet, C. A. Ford, K. Gilroy, N. Gunduz, R. A. Ridgway, E. Anderson, D. Strathdee, W. Clark, C. Nixon, J. P. Morton, A. D. Campbell, O. J. Sansom

This study shows that wild-type KRAS suppresses tumour growth and metastasis in KRAS mutant colorectal cancer while enhancing resistance to MEK inhibition.

bioRxiv · Aug 29, 2023 · PreprintCancer Biology

Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity

S. K. Fey, A. K. Najumudeen, C. A. Ford, K. Gilroy, R. Upstill-Goddard, W. Clark, C. Nixon, D. K. Chang, S. T. Barry, J. P. Morton, A. D. Campbell, O. J. Sansom

This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.

bioRxiv · Aug 29, 2023 · PreprintCancer Biology

Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target

J. Vande Voorde, A. K. Najumudeen, R. T. Steven, C. J. Nikula, A. Dexter, L. B. Zeiger, E. A. Elia, A. Nassif, A. Gonzalez-Fernandez, T. Murta, M. Gillespie, C. A. Ford, T. R. M. Lannagan, N. Vlahov, R. A. Ridgway, , O. J. Sansom

This study uses metabolomics to stratify colorectal cancer tissues and identifies adenosylhomocysteinase as a potential therapeutic target.

bioRxiv · Mar 12, 2023Cancer Biology

Mutation-induced phenotypic plasticity drives formation of a pro-metastatic tumour-intrinsic niche

J. M. Bugter, L. El Bouazzaoui, E. Kucukkose, M. L. Mills, Y. Hong, J. Sprangers, I. Jordens, D. Kokkinidi, S. Plugge, A. Venhuizen, S. Bosman, J. Hageman, N. Fenderico, K. Gilroy, D. Montiel Gonzalez, , M. M. Maurice

This study identifies mutation-induced phenotypic plasticity as a driver of a pro-metastatic tumour-intrinsic niche in BRAF-mutant colorectal cancer.

bioRxiv · Dec 22, 2022 · PreprintCancer Biology

Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture

E. Gil Vazquez, N. Nasreddin, G. N. Valbuena, E. J. Mulholland, H. L. Belnoue-Davis, H. Eggington, R. O. Schenck, V. M. Wouters, P. Wirapati, K. Gilroy, T. R. M. Lannagan, D. J. Flanagan, A. K. Najumudeen, S. Omwenga, A. M. B. McCorry, , S. J. Leedham

The paper examines stem cell population dynamics in colorectal tumors, showing that CBC-RSC admixture correlates with mutations and microenvironmental changes, and is linked to chemoresistance.

bioRxiv · Jun 11, 2022Cancer Biology

RAL GTPases mediate EGFR-driven intestinal stem cell hyperproliferation and tumourigenesis.

M. Naszai, K. Bellec, Y. Yu, A. Roman Fernandez, E. Sandilands, J. Johansson, A. D. Campbell, J. C. Norman, O. J. Sansom, D. Bryant, J. B. Cordero

This study shows RAL GTPases activate EGFR/MAPK signaling in intestinal stem cells, promoting proliferation and tumorigenesis, but are independent of oncogenic RAS.

bioRxiv · Oct 7, 2020 · PreprintCancer Biology